AbstractCapmatinib is an FDA‐approved drug to treat metastatic non‐small cell lung cancer with MET‐exon 14 skipping. Herein, the perfluoro‐tert‐butyl group, which possesses nine chemically identical fluorine atoms, was introduced on Capmatinib to afford a targeted ¹⁹F magnetic resonance imaging (MRI) probe, perfluoro‐tert‐butyl group‐derived Capmatinib (9F‐CAP). The ¹⁹F MRI concentration limit was found to be 25 mM in FLASH sequence. Molecular docking simulation, surface plasmon resonance (SPR) (with a K_d of 40.7 μM), half‐inhibitory concentration (with a IC₅₀ of 168 nM), Annexin V, and cytotoxicity assays jointly demonstrated that the 9F‐CAP targeted cMET protein specifically. Therefore, the targeted imaging capability of 9F‐CAP is of great significance for the preoperative diagnosis of specific cancers.